STAR Market contender

Short of breath? Chinese PE firms place bets on chronic respiratory disease

As global investment into healthcare dips, some pre-IPO investors hold high hopes one Chinese pharma company can take on AstraZeneca and win big in the China respiratory drug market.
January 06, 2020

Respiratory disease is a killer. Globally about 5% of all deaths are attributed to some form of lung-related illness.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media